Related Experiment Video
Updated: Feb 15, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Is Statin Therapy Safe and Effective in Patients with Chronic Kidney Disease?
Venkatesh K Raman1, Eleni Geladari2, Vasilios Papademetriou2
1MedStar Heart & Vascular Institute, MedStar Georgetown University Hospital, Washington, DC,United States.
Insights
Statin therapy for chronic kidney disease (CKD) patients shows reduced effectiveness, especially in dialysis patients. Alternative lipid therapies may be needed for cardiovascular risk management in CKD.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Chronic kidney disease (CKD) is linked to dyslipidemia and heightened cardiovascular risk.
- This risk persists even in early CKD stages before substantial kidney function decline.
- Statins are key for cardiovascular prevention in at-risk individuals.
Purpose of the Study:
- To review current knowledge on statin therapy in CKD patients.
- To examine statin effects on renal outcomes and safety in this population.
- To discuss alternative lipid-lowering therapies for CKD.
Main Methods:
- Literature review of studies on statin efficacy and safety in CKD.
- Analysis of cardiovascular event rates in CKD patients on statins.
- Evaluation of renal outcomes and safety profiles.
Main Results:
- Statin efficacy appears diminished across the CKD spectrum, particularly in hemodialysis patients.
- Cardiovascular risk remains elevated in CKD patients despite statin use.
- Safety data in CKD patients requires careful consideration.
Conclusions:
- Statin therapy's effectiveness in CKD, especially end-stage renal disease, is questionable.
- Further research into alternative lipid management strategies is warranted for CKD patients.
- Optimizing cardiovascular risk reduction in CKD necessitates tailored approaches.
Abstract:
Chronic kidney disease (CKD) is associated with dyslipidemia and increased cardiovascular risk. This elevated risk for cardiovascular events exists even in the largest subpopulation with milder stages of CKD, prior to the development of significant reductions in renal excretory function. Statin therapy is a critical component of primary and secondary cardiovascular prevention efforts for at-risk patients. Efficacy in the CKD population, however, has appeared less robust across the spectrum of CKD, particularly in hemodialysis patients. This article will review the current state of knowledge on statin therapy in CKD, effects on renal outcomes, safety in this population and alternative lipid therapies.
More Related Videos
05:33Author Spotlight: Alleviating Nausea and Vomiting in Pregnancy with Safe and Effective Auricular Acupuncture
Published on: August 4, 2023
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-I: Introduction